Introduction {#sec1-1}
============

Ghrelin is a 28-amino acid that is produced in the stomach. Other organs such as liver heart and pancreas can also produce ghrelin but in lower levels \[[@ref1]\]. Strong evidence indicates the effects of ghrelin in its potential role in the pathogenesis of obesity, insulin resistance (IR) and types 2 diabetes \[[@ref2]\].

More recently, research on ghrelin has improved our understanding of the mechanisms involve food intake, fat accumulation, and the development of other metabolic disturbances \[[@ref3]\].

The role of ghrelin in the regulation of glucose was initially hypothesized after an observation of a negative correlation of insulin and ghrelin \[[@ref4]\].

One year later Schofl et al. \[[@ref5]\] supported the involvement of ghrelin in the development of IR and typed two diabetes. Total ghrelin levels have also been found to be negatively correlated with IR in children and adolescents \[[@ref6]\].

Food intake is the most important factor that influences ghrelin levels. Usually, total ghrelin levels are rising during the night and decrease after breakfast \[[@ref7]\]. A long-term high fat diet has found to reduce plasma total ghrelin levels and stomach content \[[@ref8]\]. Also, many studies have reported that ghrelin levels are negatively associated with body mass index (BMI) \[[@ref9], [@ref10]\].

We hypothesized that obese individuals would present with elevated fasting ghrelin levels and there is no relationship between ghrelin and insulin levels.

Methods {#sec1-2}
=======

Twenty healthy subjects (13 with normal weight and seven obese) participated in the study aged 20-22 years old. A detailed medical history was taken by the clinic's doctor. Subjects with a medical history of liver, renal, or heart or taking any medications and supplements were excluded from the study. The study received approval from the ethical committees of "Zayed University" and "Doctors Medical Center" while all subjects signed a consent form.

Body weight and height were collected for all subjects using SECA 600 model while obesity was defined as BMI\>30 kg/m^2^, according to the criteria of International Obesity Task Force \[[@ref11]\].

Plasma ghrelin, glucose, insulin and C-reactive protein (CRP) levels were measured in the morning after fasting overnight. Blood samples were drawn by a certified nurse by venipuncture into 10-ml empty evacuated placed on ice tubes. The tubes were immediately centrifuged at 2000 x g for 10 min. Plasma ghrelin levels were measure with the immunochemilunometric assay (IDS, SMBH, Germany) with an inter-assay coefficient of 6.2%. Plasma glucose levels were measured using a hexokinase enzymatic reference method (Cobas, Roche USA). Fasting insulin levels were measured using ECLIA method (Cobas 6000, Roche, USA) while CPR was measure with Immunoturbidimetry (Cobas 6000, Roche, USA). HOMA-IR was used to evaluate insulin resistance (fasting serum insulin (pmol/l) × fasting plasma glucose (mmol l^-1^)/22.5) \[[@ref12]\].

Statistical Analysis {#sec2-1}
--------------------

Fasting levels of ghrelin, glucose and insulin were compared by a *t*-test between normal and obese groups. Pearson's correlations were calculated between anthropometric and biochemical variances and ghrelin levels. Moreover, the effect of several variables on ghrelin concentrations was considered with multiple linear regression analysis. In the regression model, we verified ghrelin as a dependent variable and included weight, BMI, glucose, Insulin, glucose and HOMA-IR as independent variables. Values with P \< 0.05 were considered statistically significant.

Results {#sec1-3}
=======

Fasting plasma levels were significantly lower in an obese subject compared to normal ones ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). Also, BMI, plasma insulin and HOMA-IR were significantly higher in the obese group ([Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of Normal and Obese subjects

                    Normal (n = 13)   OB (n = 7)   p-value
  ----------------- ----------------- ------------ ---------------------------------------
  Age, y            21±0.8            21.±2.07     0.298
  Height, cm        159±8.2           161±3.7      0.183
  Weight, Kg        53±8.7            79+11        0.001[\*](#t1f1){ref-type="table-fn"}
  BMI, kg/m\^2      20.6±3            31.3±2.1     0.001[\*](#t1f1){ref-type="table-fn"}
  CRP               1.2±1.1           2.0±1.0      0.065
  Glucose, mmol/l   5.1±6.5           5.5±6.7      0.072
  Insulin, pmol/l   8.2±2.7           14.5±2.3     0.041[\*](#t1f1){ref-type="table-fn"}
  HOMA-IR           1.85±0.5          3.54±0.8     0.004[\*](#t1f1){ref-type="table-fn"}
  Ghrelin, pg/ml    541±202           440±140      0.002[\*](#t1f1){ref-type="table-fn"}

Data is presented as mean ± SD;

P \< 0.05 = Statistically significantly difference.

![Ghrelin levels of obese subjects were statistically significant compare to normal ones (P \< 0.005)](OAMJMS-5-699-g001){#F1}

Fasting plasma ghrelin was negatively correlated with BMI (r= -0.77, P\<0.001), fasting insulin levels (r= -0.55, P \< 0.001) and HOMA-IR (r = -0.66, P \< 0.001). There was no correlation between ghrelin and glucose ([Table 2](#T2){ref-type="table"}).

###### 

Pearson's Correlation between Ghrelin and other variables

            r       p-value
  --------- ------- ---------------------------------------
  Age       0.51    0.332
  Height    -0.34   0.566
  Weight    -0.78   0.002[\*](#t2f1){ref-type="table-fn"}
  BMI       -0.77   0.001[\*](#t2f1){ref-type="table-fn"}
  Glucose   -0.51   0.455
  Insulin   -0.55   0.001[\*](#t2f1){ref-type="table-fn"}
  HOMA-IR   -0.66   0.001[\*](#t2f1){ref-type="table-fn"}

P\<0.05: Statistically significant.

In multiple regression analysis, insulin levels (Beta: -2.66, 95% CI: -2.49, -2.78, P \< 0.001) HOMA-IR (Beta: -2.41, 95% CI: -2.33, -2.55, P \< 0.001) and BMI (Beta: -1.77, 95% CI: -1.66, -1.89, P \< 0.001) were significant independent determinants of fasting ghrelin ([Table 3](#T3){ref-type="table"}).

###### 

Multiple regression analysis of Ghrelin with anthropometric and biochemical variables

  Variable   Beta    95% CI         P
  ---------- ------- -------------- ---------------------------------------
  Weight     -0.44   -0.32, -0.55   0.505
  BMI        -1.77   -1.66, -1.89   0.001[\*](#t3f1){ref-type="table-fn"}
  Glucose    -0.32   -0.37, -0,49   0.668
  Insulin    -2.66   -2.49, -2.78   0.001[\*](#t3f1){ref-type="table-fn"}
  HOMA-IR    -2.41   -2.33, -2.55   0.001[\*](#t3f1){ref-type="table-fn"}

p \< 0.05: Statistically significant.

Discussion {#sec1-4}
==========

In our study contrary to our hypothesis, obese subjects have lower concentrations of ghrelin and higher insulin levels that the age-matched lean control subjects. This is an indication that ghrelin is downregulated in human obesity. This result may be because of elevated insulin levels since ghrelin levels were independently associated with insulin and HOMA-IR. These findings are in agreement with other research studies \[[@ref13], [@ref14]\]. Ghrelin was shown to inhibit insulin secretion from pancreatic islets in rodents \[[@ref15]\].

Ghrelin secretion may be affected by adiposity through insulin and glucose metabolism \[[@ref16]\]. Studies performed in humans demonstrated that i.v. Administration of insulin induces a fall in ghrelin levels \[[@ref17]\]. Thus, reduced ghrelin levels in obesity may be the consequence of increased insulin levels in these subjects.

In our study, ghrelin levels were negatively correlated with body weight and independently associated with BMI. Research evidence shows that plasma ghrelin levels are negatively correlated with body mass index and body fat percentage \[[@ref18]\]. Also, reduced ghrelin secretion in obese patients was found to be an adaptive mechanism to a long-term positive energy balance \[[@ref19]\].

The present study has some limitations that should be addressed. The small sample of the study has an important influence on the results. Also, we did not take in consideration any dietary habits, genetic information and socioeconomic factors that could also play an important role in obesity. Moreover, this was a one-time measure and may not represent the reality of the indices. Nevertheless, the results will provide some evidence of the relation of fasting ghrelin levels with insulin resistance and give some light on the pathogenesis of human obesity.

In conclusion, Ghrelin is deregulated in obesity and associated with insulin and insulin resistance and thus may be considered a suitable target for the management of insulin resistance. More studies are needed to elucidate the effects of ghrelin in the pathogenesis of human obesity.
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